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Which oral antifungal is best  
for toenail onychomycosis?
Terbinafine,	250	mg	taken	daily	for	12	
weeks,	is	the	best	regimen	for	toenail	
onychomycosis	due	to	better	clinical	and	
mycologic	cure	rates,	tolerability,	and	cost	
effectiveness	(strength	of	recommendation	
[sor]:	A,	meta-analyses).
This expensive treatment  
is not always a high priority
In	my	practice	of	mostly	uninsured	
patients,	onychomycosis	treatment	is	not	
a	high	priority.	The	recommended	drug,	
terbinafine,	is	costly	and	not	available	
as	a	generic.	since	this	is	primarily	a	
cosmetic	problem,	we	usually	don’t	treat	
it	in	my	population.	In	the	rare	case	that	
someone	is	willing	to	pay	out	of	pocket,	
however,	I	will	now	use	terbinafine,	based	
on	this	review.	At	one	of	my	practices,	
itraconazole	was	available	at	a	reduced	
price,	but	that	discount	is	outweighed	by	
the	superior	safety	profile	of	terbinafine.
José E. Rodríguez, MD
Florida	state	university	College	of	Medicine,	
Tallahassee
Clinical commentary
Evidence-based answer
z Evidence summary
Fungal infections of the nail (onychomy-
cosis) are often treated for relief of local 
symptoms and cosmetic reasons. Gris-
eofulvin, fluconazole, itraconazole, and 
terbinafine have all been used orally. 
A meta-analysis comparing the effi-
cacy of terbinafine (Lamisil), pulse-dosed 
and continuous-dosed itraconazole (Spo-
ranox), fluconazole (Diflucan), and gris-
eofulvin showed mycological cure rates 
of varying degrees for each treatment 
(TablE).1 Another meta-analysis of 6 
studies comparing terbinafine with itra-
conazole reported odds ratios ranging 
from 1.8 (95% confidence interval [CI], 
1.1–2.8) to 2.9 (95% CI, 1.9–4.1), indi-
cating an 80% to 190% increased like-
lihood of clinical cure with terbinafine 
compared with itraconazole.2 
lower relapse rates  
with terbinafine
Longer-term mycologic cure and clinical 
relapse rates have also been reported. A 
5-year blinded prospective study found 
long-term mycologic cures of 46% for 
terbinafine vs 13% for itraconazole 
(number needed to treat [NNT]=4.3). 
This study also showed a lower clinical 
relapse for terbinafine (21% vs 48%; 
NNT=3.7).3 A cost-efficacy analysis of 
terbinafine, itraconazole, and griseoful-
vin found terbinafine to be the most cost-
effective (TablE).4 
A randomized, double-blind, con-
trolled trial compared daily terbinafine 
with pulse-dose terbinafine.5 Daily 
terbinafine (250 mg for 3 months) had a 
70.9% mycologic cure, while pulse-dose 
terbinafine (500 mg daily for 1 week per 
Terbinafine  
has the best rates 
of long-term cure
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tablE
TrEATmEnT myCologiCAl  CosT PEr CurE* 
 CurE rATEs 
terbinafine	 76%	(±	3%)	 $	645	
(continuous)
itraconazole	
(pulse-dose)	 63%	(±	7%)	 $	856
itraconazole	
(continuous)	 59%	(±	5%)	 $	1845
Griseofulvin	 60%	(±	6%)	 $	2722
Fluconazole	 48%	(±	5%)	 Not	reported
*	Cost	includes	drug,	monitoring,	and	office	visits	(in	1996	dollars).
Efficacy and cost of treating toenail onychomycosis1,4
month for 3 months) had only a 58.7% 
mycologic cure (relative risk [RR]=1.21 
[95% CI, 1.02–1.43]; NNT=8.2). There 
was no significant difference in tolerabil-
ity of the regimens.
Terbinafine is well-tolerated by most 
patients. A telephone survey after treat-
ment with daily terbinafine or pulse-dose 
itraconazole reported greater ease and 
convenience, and higher overall satisfac-
tion with continuous terbinafine vs pulse-
dose itraconazole.6 
A multicenter trial of diabetic patients 
with onychomycosis (mean ± SD age, 
55.7 ± 11.7 years) revealed that terbin-
afine had comparable efficacy and caused 
no hypoglycemic reactions in this group, 
who were being treated with insulin or 
oral hypoglycemics.7 The terbinafine pre-
scribing information suggests not using 
the drug for patients with chronic or ac-
tive liver disease and recommends check-
ing a pretreatment AST and ALT.8
Recommendations from others
Guidelines from the British Associa-
tion of Dermatologists point out that 
terbinafine is superior to itraconazole, 
and consider it a first-line treatment be-
cause it has a better cure rate and lower 
relapse rate.9 UpToDate suggests oral 
terbinafine as initial treatment for 
onychomycosis at a dose of 250 mg daily 
for 12 weeks.10  n
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Do not prescribe  
terbinafine for  
patients with 
chronic or active 
liver disease
